79$/KG
69$/KG
Product Detailed Description
Liposomal GABA 70% is a premium-grade dietary supplement ingredient delivering gamma-aminobutyric acid (GABA) in an advanced liposomal delivery system. GABA (CAS 56-12-2) is a naturally occurring inhibitory neurotransmitter in the human central nervous system and is also an important functional amino acid, widely present in the brain, nervous system, and various tissues within the body. The human body can synthesize a small amount of GABA on its own, but as stress increases, staying up late, and aging occur, the level of GABA in the body tends to be insufficient, requiring external supplementation.
GABA is the major inhibitory neurotransmitter in the brain, and imbalances of this neurotransmitter are associated with neurological diseases such as Alzheimer‘s and Parkinson’s disease, and psychological disorders including anxiety, depression, and stress. Emerging evidence has demonstrated that changes in both circulating and brain levels of GABA are associated with changes in gut microbiota composition, and that changes in GABA levels and microbiota composition play a role in modulating mental health.
Conventional oral GABA faces fundamental bioavailability challenges. It has long been believed that GABA cannot cross the blood-brain barrier, but studies that have assessed this issue are often contradictory and range widely in their employed methods. Conventional GABA supplementation faces significant bioavailability challenges due to the blood-brain barrier and poor gastrointestinal absorption.
Liposomal encapsulation provides three critical advantages:
1. Gastric Protection — The phospholipid bilayer shields GABA from stomach acid degradation, significantly enhancing its stability and biological utilization rate, allowing GABA to be absorbed and utilized by the body more efficiently.
2. Blood-Brain Barrier Penetration — In contrast to GABA, which only poorly penetrates into the brain after systemic administration, a liposomal suspension of phosphatidylserine (PS) and GABA (GABA-PS; liposome-entrapped GABA) has been shown to cross the blood-brain barrier and exert anticonvulsant effects in animal models.
3. Enhanced Cellular Uptake — Liposomal encapsulation technology addresses bioavailability limitations by encasing GABA molecules within lipid bilayers, dramatically improving cellular uptake and therapeutic efficacy. The liposomal delivery system increases GABA absorption rates by up to 90% compared to standard formulations.
High Purity — Standardized to ≥70% GABA by HPLC, ensuring consistent active content.
Liposomal Enhancement — Phospholipid bilayer encapsulation protects GABA from gastric acid degradation and significantly enhances stability and biological utilization rate.
Blood-Brain Barrier Support — Liposomal GABA has been shown to cross the blood-brain barrier and exert central nervous system effects in animal models.
Clinically Validated for Stress Relief — Clinical studies with GABA have shown it to produce significant antistress effects, as evidenced by changes in brain-wave patterns, pupil diameter, and heart rate, as well as reduction of salivary cortisol and chromogranin A levels.
Sleep Quality Support — Oral consumption of 100 mg GABA for a week significantly shortened sleep latency and increased total non-rapid eye movement (non-REM) sleep time.
Gut-Brain Axis Modulation — GABA is recognized as a potential postbiotic mediator in the gut-brain axis, modulating mental health through microbiota composition changes.
Water-Dispersible — Good water dispersibility; suitable for capsules, tablets, powder drink mixes, and functional beverages.
Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.
| Application | Recommended Usage | Notes |
|---|---|---|
| Capsules / Tablets | 100–200 mg per serving | 1–2 capsules daily; can be taken up to three times daily |
| Functional Beverages | 50–100 mg per 250 mL | Water-dispersible; suitable for RTD formats |
| Powdered Drink Mixes | 100–300 mg per sachet | Blend with L-theanine for synergistic calming support |
| Sleep Support Formulas | 100–300 mg per serving | Take 30–60 minutes before bedtime |
| Stress Relief Formulas | 100–200 mg per serving | Often combined with L-theanine, magnesium, or ashwagandha |
Clinical studies and commercial products commonly recommend 100–300 mg of GABA per day. The typical dosage is 100 to 200 mg up to three times daily, with a general guideline of no more than 1,000 mg within a 4-hour period and no more than 3,000 mg within a 24-hour period. A randomized controlled trial in 30 women administered 200 mg of GABA daily, with many studies showing that doses ranging from 100 to 200 milligrams a day are effective. Oral consumption of 100 mg GABA for a week significantly shortened sleep latency and increased total non-REM sleep time. For general stress and sleep support, 100–200 mg daily is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.
Stock Orders: 3–5 business days after payment confirmation.
Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.
Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.
Coverage: Worldwide shipping, including remote areas.
GABA Encyclopedia — Scientific Background
Gamma-aminobutyric acid (GABA) is a naturally occurring inhibitory neurotransmitter in the human central nervous system and is also an important functional amino acid, widely present in the brain, nervous system, and various tissues within the body. It is the primary inhibitory neurotransmitter in the central nervous system (CNS), playing a pivotal role in maintaining the delicate balance between inhibitory and excitatory neurotransmission. GABA is synthesized from glutamate via the enzyme glutamic acid decarboxylase, which exhibits significantly lower expression in the substantia nigra and frontal cortex with increased age.
| Property | Value |
|---|---|
| CAS No. | 56-12-2 |
| Molecular Formula | C₄H₉NO₂ |
| Molecular Weight | 103.12 g/mol |
| IUPAC Name | 4-Aminobutanoic acid |
| Appearance | White to off-white crystalline powder |
| Solubility | Soluble in water |
| Odor | Slight characteristic odor |
GABA is the major inhibitory neurotransmitter in the brain. It activates specific GABA receptors in downstream cells and is expressed in the CNS. The GABAA receptors are involved in fast inhibitory transmission via conductance of chloride. Low levels or decreased GABA function in the brain are associated with several psychiatric and neurological disorders, but most primarily anxiety, depression, insomnia, and epilepsy.
Emerging evidence has demonstrated that changes in both circulating and brain levels of GABA are associated with changes in gut microbiota composition and that changes in GABA levels and microbiota composition play a role in modulating mental health. GABA is recognized as a potential postbiotic mediator in the gut-brain axis, and this recent research has raised the possibility that GABA may be a potent mediator of the gut-brain axis. Changes in GABA levels and microbiota composition play a role in modulating mental health, including anxiety, depression, stress, epilepsy, autism spectrum disorder, and attention deficit hyperactivity disorder.
Peripheral immune cells—including macrophages, dendritic cells, and T lymphocytes—possess functional GABA receptor complexes. The binding of GABA to these immune-associated receptors triggers distinct anti-inflammatory cascades. GABAergic activation actively down-regulates the secretion of pro-inflammatory cytokines while simultaneously suppressing the excessive proliferation of autoreactive T cells.
Specific GABA-enriched dietary interventions display profound metabolic benefits, actively maintaining blood glucose homeostasis, improving glycolipid metabolism, and reversing gut microbiota dysbiosis in type 2 diabetic models.
GABA exerts its effects primarily through two classes of receptors: GABAA receptors (ionotropic, mediating fast inhibitory transmission via chloride conductance) and GABAB receptors (metabotropic, G-protein-coupled). Currently, many popular antianxiety drugs—the sedative-hypnotics—interact primarily with GABA receptors. These drugs include the benzodiazepine drugs like alprazolam and diazepam, as well as drugs like zolpidem tartrate (Ambien) and baclofen.
Clinical studies with GABA have shown it to produce significant antistress effects. Specifically, GABA has been shown to produce relaxation, as evidenced by changes in brain-wave patterns, pupil diameter, and heart rate, as well as reduce markers of stress, including salivary cortisol and chromogranin A levels. These effects are thought to be the result of activation of the parasympathetic nervous system rather than GABA crossing the blood-brain barrier.
GABA-producing microorganisms isolated from human gut and food sources contribute to circulating GABA levels. Research suggests that GABA may be a potent mediator of the gut-brain axis, with changes in GABA levels and microbiota composition playing a role in modulating mental health.
Despite its essential physiological functions, native GABA presents significant bioavailability challenges. It has long been believed that GABA cannot cross the blood-brain barrier, and conventional GABA supplementation faces significant bioavailability challenges due to the blood-brain barrier and poor gastrointestinal absorption. Studies that have assessed whether GABA can cross the blood-brain barrier are often contradictory and range widely in their employed methods.
Liposomal encapsulation addresses these limitations through a biomimetic phospholipid bilayer that protects GABA during digestive transit, prevents premature metabolism, and facilitates crossing of the blood-brain barrier. In contrast to GABA, which only poorly penetrates into the brain after systemic administration, a liposomal suspension of phosphatidylserine and GABA has been shown to cross the blood-brain barrier and exert anticonvulsant effects in animal models. The liposomal delivery system increases GABA absorption rates by up to 90% compared to standard formulations.
Liposomal encapsulation of GABA provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the GABA molecule, forming a shield that protects it from gastric acid degradation and enzymatic metabolism. This delivery system:
Protects GABA from gastric acid degradation
Significantly enhances stability and biological utilization rate
Facilitates crossing of the blood-brain barrier
Enhances cellular uptake through membrane fusion
Liposomal GABA is a new generation of highly absorbable nutritional raw material that is encapsulated using liposome technology and wraps GABA within a phospholipid bilayer structure. It can protect GABA from stomach acid, significantly enhancing its stability and biological utilization rate, allowing GABA to be absorbed and utilized by the body more efficiently.
Clinical studies with GABA have shown it to produce significant antistress effects. Specifically, GABA has been shown to produce relaxation, as evidenced by changes in brain-wave patterns, pupil diameter, and heart rate, as well as reduce markers of stress, including salivary cortisol and chromogranin A levels. These effects are thought to be the result of activation of the parasympathetic nervous system.
Oral consumption of a beverage containing 50 mg of GABA reduced stress (CgA) and fatigue (cortisol) in subjective and objective assessments. Oral consumption of 100 mg GABA for a week significantly shortened sleep latency and increased total non-rapid eye movement (non-REM) sleep time. Studies indicate that GABA can improve relaxation and concentration during times of stress, reduce sleep latency, and increase the time spent in deep sleep.
In animal models, a liposomal suspension of phosphatidylserine and GABA (GABA-PS) has been shown to cross the blood-brain barrier and exert anticonvulsant effects in isoniazid- and penicillin-induced seizures in rats. A pilot add-on study in 42 patients with drug-resistant epilepsy investigated the effect of GABA-PS. Patients with focal onset seizures showed no significant improvement; on the other hand, there was a remarkable decrease in absence seizures, linearly related to the dose of GABA-PS.
The global GABA liposomal market was valued at $0.3 billion in 2025 and is projected to expand to $0.7 billion by 2034, representing a steady compound annual growth rate of 9.8% throughout the forecast period. The primary driver of market expansion is the escalating prevalence of stress-related and anxiety disorders across global populations. According to the World Health Organization, over 280 million people worldwide suffer from depression and anxiety-related conditions, creating substantial demand for effective, natural therapeutic interventions.
GABA is generally well tolerated at commonly used doses. A review conducted by the EPA indicated that studies in the literature involving prolonged chronic administration of large doses of GABA to rats and dogs (up to 1 g/kg/day) reported no signs of toxicity or untoward effects. A 2025 preclinical mouse study demonstrated that long-term oral GABA supplementation at 10–20 mg/kg/day produced anxiolytic effects without any detectable adverse outcomes. A repeated oral administration study demonstrated that GABA produced through Lactobacillus hilgardii-mediated fermentation up to 2,500 mg/kg/day (the NOAEL) in rats does not adversely affect parental health or reproductive function. Common side effects may include abdominal discomfort, headache, drowsiness, and a burning sensation in the throat. Long-term safety data are still limited.
Regulatory authorities globally have progressively endorsed GABA as a legitimate dietary component:
United States — GABA is regulated as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) and has achieved Generally Recognized as Safe (GRAS) status by the FDA for inclusion in diverse food matrices. FDA GRAS Notice No. GRN 000595 has been filed for GABA for use as an ingredient in snack bars, breakfast cereals, processed cheese, chewing gum, yogurts, hard and soft candies, chocolate, and beverages, at a level of 100 milligrams of GABA per serving.
China — The Chinese Ministry of Health officially approved GABA as a new resource food in 2009, stipulating a maximum daily intake of 500 mg.
Japan — GABA is one of the most frequently notified active ingredients approved under the Foods with Function Claims (FFC) and Foods for Specified Health Uses (FOSHU) systems, widely utilized in functional beverages and snacks for stress relief.
European Union — The EU permits the use of GABA in food supplements, subject to specific national guidelines and EFSA evaluations. GABA is considered safe at the proposed maximum combined intake level of 7.5 mg/kg body weight/day.
Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.
This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.
79$/KG
69$/KG
RELATED
RELATED
This website uses cookies to ensure you get the best experience on our website.
Español
Français
Deutsch
日本語
한국어
Phone
Comment
（0）